Oral contraceptives and the risk of venous thromboembolism: An update: No. 252, December 2010

International Journal of Gynecology and Obstetrics

Volumn 112, Issue 3, 2011, Pages 252-256

  Reid, Robert ^a   Leyland, Nicholas ^a   Wolfman, Wendy ^a   Allaire, Catherine ^a   Awadalla, Alaa ^a   Best, Carolyn ^a   Dunn, Sheila ^a   Lemyre, Madeleine ^a   Marcoux, Violaine ^a   Menard, Chantal ^a   Potestio, Frank ^a   Rittenberg, David ^a   Singh, Sukhbir ^a   Senikas, Vyta ^a  

^a NONE

Author keywords

Contraception; Hormonal contraception; Oral contraceptives; Venous thromboembolism; VTE

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

ARTICLE; CONTRACEPTION; HORMONAL CONTRACEPTION; HUMAN; MEDICAL LITERATURE; MEDICAL RESEARCH; MEDICAL SOCIETY; MEDLINE; OBSERVATIONAL STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REGISTER; RISK ASSESSMENT; TECHNOLOGY; VENOUS THROMBOEMBOLISM; CANADA; CHEMICALLY INDUCED DISORDER; FEMALE; RISK FACTOR;

CANADA; CONTRACEPTIVES, ORAL; FEMALE; HUMANS; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 79951609388     PISSN: 00207292     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijgo.2010.12.003     Document Type: Article

References (35)

1. ACOG Noncontraceptive uses of hormonal contraception. ACOG Practice Bulletin No. 110, Jan 2010. Obstet Gynecol 2010;115:206-18.
2. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton III LJ. Trends in the incidence of deep vein thrombosis and pulmonary embolism. A 25-year population-based study. Arch Intern Med 1998;158:585-93. (Pubitemid 28144815)
3. Pomp ER, Rosendaal FR, Doggen CJM. Smoking increases the risk of venous thrombosis and acts synergistically with oral contraceptive use. Am J Hematol 2008;83:97-102.
4. Cannegieter SC, Doggen CMJ, van Houwelingen HC, Rosendaal FR. Travel-related venous thrombosis: results from a large population-based case control study (MEGA Study). PLoS Med 2006;3(8):e307, doi:10.1371/journal.pmed. 0030307. (Pubitemid 44338363)
5. Pomp ER, le Cessie S, Rosendaal FR, Doggen CJR. Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol 2007;139:289-96. (Pubitemid 47493087)
6. Ros HS, Lichtenstein P, Belloco R, PeterssonG, Cnattingius S. Increased risks of circulatory diseases in late pregnancy and puerperium. Epidemiology 2001;12:456-60. (Pubitemid 32566488)
7. Pomp ER, Lenselink AM, Rosendaal FR, Doggen CJM. Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost 2008;6:632-7. (Pubitemid 351404930)
8. Heinemann LAJ, Dinger JC. Range of published estimates of venous thromboembolism incidence in young women. Contraception 2007;75:328-36. (Pubitemid 46551070)
9. Dinger JC, Heinemann LAJ, Kuhl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance study on Oral Contraceptives based on 142, 475 women-years of observation. Contraception 2007;75:344-54. (Pubitemid 46551071)
10. Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton III LJ. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 2005;143:697-706.
11. Ory HW. Mortality associated with fertility and fertility control: 1983. Fam Plann Perspect 1983;15:57-63.
12. Gerstman BB, Piper JM, Tomita DK, Ferguson WJ, Stadel BV, Lundin FE. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 1991;133:32-7.
13. Lidegaard L, Løkkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009;339: b2890.
14. Severinsen MT, Kristensen SR, Overvad K, Dethlefsen C, Tjønneland A, Johnsen SP. Venous thromboembolism discharge diagnoses in the Danish National Patient Registry should be used with caution. J Clin Epidemiol 2010;63:223-8.
15. Gallo MF, Nanda K, Grimes DA, Schulz KF. Twenty micrograms vs. N20 microg estrogen oral contraceptives for contraception: systematic review of randomized controlled trials. Contraception 2005;71:162-9. (Pubitemid 40250196)
16. Mills A. Combined oral contraception and the risk of venous thromboembolism. Hum Reprod 1997;12:2595-8. (Pubitemid 28031714)
17. Goodyear-Smith A, Arroll B. Termination of pregnancy following panic-stopping of oral contraceptives. Contraception 2002;66:163-7. (Pubitemid 35217866)
18. Spitzer WO. The aftermath of a pill scare: regression to reassurance. Hum Reprod Update 1999;5:736-45. (Pubitemid 30034895)
19. Lewis MA, MacRae KD, Kuhl-Habichl D, Bruppacher R, Heinemann LA, Spitzer WO. The differential risk of oral contraceptives: the impact of full exposure history. Hum Reprod 1999;14:1493-9. (Pubitemid 29265441)
20. Hennessy S, Berlin JA, Kinman JL, Margolis DJ, Marcus SM, Strom BL. Risk of venous thromboembolism from oral contraceptives containing gestodene and desogestrel versus levonorgestrel: a meta-analysis and formal sensitivity analysis. Contraception 2001;64:125-33. (Pubitemid 33042599)
21. Spitzer WO. The 1995 pill scare revisited: anatomy of a non-epidemic. Hum Reprod 1997;12:2347-57. (Pubitemid 27522186)
22. Suissa S, Blais L, Spitzer WO, Cusson J, Lewis M, Heineman L. First time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception 1997;56:141-6. (Pubitemid 27450823)
23. Herings RM, Urquhart J, Leufkens HG. Venous thromboembolism among new users of different oral contraceptives. Lancet 1999;354:127-8. (Pubitemid 29313151)
24. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med 2000;160:49-52. (Pubitemid 30040972)
25. Cushman M, Kuller LH, Prentice R, Rodabough RJ, Psaty BM, Stafford RS, et al. Estrogen plus progestin and the risk of venous thrombosis. JAMA 2004;292: 1573-80. (Pubitemid 39314963)
26. Seeger JD, Loughlin J, Eng PM, Clifford CR, Cutone J, Walker AM. Risk of thromboembolism in women taking ethinyl estradiol/drospirenone and other oral contraceptives. Obstet Gynecol 2007;110:587-93. (Pubitemid 47359582)
27. Eng PM, Seeger JD, Loughlin J, Clifford CR, Mentor S, Walker AM. Supplementary data collection with case-cohort analysis to address potential confounding in a cohort study of thromboembolism in oral contraceptive initiators matched on claims-based propensity scores. Pharmacoepidemiol Drug Saf 2008;17:297-305. (Pubitemid 351404040)
28. Van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJM, Rosendaal FR. Effects of oestrogen dose and progestogen type on venous thrombotic risk associated with oral contraceptives: results of the MEGA casecontrol study. BMJ 2009;339:b2921.
29. Yasmin physician labeling. Available at:http://www.yasmin-us.com/index. html Accessed September 29, 2010.
30. Shapiro S, Dinger J. Risk of VTE among users of oral contraceptives [reply to letter to editor]. J Fam Plann Reprod Health Care 2010;36:104-5.
31. Spitzer WO. Bias or causality: Interpreting recent evidence of oral contraceptive studies. Am J Obstet Gynecol 1998;179:S43-50. (Pubitemid 28447222)
32. Dinger J. Oral contraceptives and venous thromboembolism: old questions revisited. J Fam Plann Reprod Health Care 2009;35:211-3.
33. Shapiro S. Causation, bias and confounding: a hitchhiker's guide to the epidemiological galaxy. Part 3: principles of causality in epidemiological research: statistical stability, dose- and duration-response effects, internal and external consistency, analogy and biological plausibility. J Fam Plann Reprod Health Care 2008;34:261-4.
34. Lidegaard O. Risk of venous thromboembolism among users of oral contraceptives: a review of two recently published studies. J Fam Plann Reprod Health Care 2010;36:103-4.
35. Woolf SH, Battista RN, Angerson GM, Logan AG, Eel W. Canadian Task Force on Preventive Health Care. New grades for recommendations from the Canadian Task Force on Preventive Health Care. CMAJ 2003;169:207-8.